An osteogenic helioxanthin derivative suppresses the formation of bone-resorbing osteoclasts

Giannoudis, 2007, Fracture healing in osteoporotic fractures: is it really different? A basic science perspective, Injury, 38, S90, 10.1016/j.injury.2007.02.014 Emara, 2015, Recent biological trends in management of fracture non-union, World J Orthop, 6, 623, 10.5312/wjo.v6.i8.623 Schwartz, 2007, Diabetes, fracture, and bone fragility, Curr Osteoporos Rep, 5, 105, 10.1007/s11914-007-0025-x Lo, 2012, The role of small molecules in musculoskeletal regeneration, Regen Med, 7, 535, 10.2217/rme.12.33 Holliday, 1997, Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism, Am J Physiol, 272, F283 Ohba, 2007, A novel osteogenic helioxanthin-derivative acts in a BMP-dependent manner, Biochem Biophys Res Commun, 357, 854, 10.1016/j.bbrc.2007.03.173 Nakajima, 2010, Enhancement of bone formation ex vivo and in vivo by a helioxanthin-derivative, Biochem Biophys Res Commun, 395, 502, 10.1016/j.bbrc.2010.04.041 Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase iii osteoporosis treatment study group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 Essayan, 2001, Cyclic nucleotide phosphodiesterases, J Allergy Clin Immunol, 108, 671, 10.1067/mai.2001.119555 Miyamoto, 2006, Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis, J Bone Miner Metab, 24, 260, 10.1007/s00774-006-0682-3 Liou, 2013, KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways, PLoS One, 8 Maeda, 2013, Bone healing by sterilizable calcium phosphate tetrapods eluting osteogenic molecules, Biomaterials, 34, 5530, 10.1016/j.biomaterials.2013.03.089 Emori, 2015, A new method for measuring osteoclast formation by electrical impedance, J Pharmacol Sci, 128, 87, 10.1016/j.jphs.2015.05.002 Yasui, 2001, New clinical applications of xanthine derivatives: modulatory actions on leukocyte survival and function, Int J Hematol, 73, 87, 10.1007/BF02981908 Barnes, 2005, Theophylline in chronic obstructive pulmonary disease: new horizons, Proc Am Thorac Soc, 2, 334, 10.1513/pats.200504-024SR MacIntyre, 1991, Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP, Proc. Natl. Acad. Sci. U. S. A., 88, 2936, 10.1073/pnas.88.7.2936 Kasten, 1994, Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase, Proc. Natl. Acad. Sci. U. S. A., 91, 3569, 10.1073/pnas.91.9.3569 Iwaki, 2016, Nicorandil inhibits osteoclast differentiation in vitro, Eur J Pharmacol, 793, 14, 10.1016/j.ejphar.2016.10.034 Yaroslavskiy, 2005, NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP, J Cell Sci, 118, 5479, 10.1242/jcs.02655 Davison, 2014, Osteoclast resorption of beta-tricalcium phosphate controlled by surface architecture, Biomaterials, 35, 7441, 10.1016/j.biomaterials.2014.05.048 Costa, 2013, The differential regulation of osteoblast and osteoclast activity by surface topography of hydroxyapatite coatings, Biomaterials, 34, 7215, 10.1016/j.biomaterials.2013.06.014 Semmler, 1993, Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity, Immunology, 78, 520